Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02896868 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3041658 in Participants With Skin Diseases
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02896868 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 60 participants.
The verdict
NCT02896868, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The main purpose of this study is to investigate the safety and tolerability of the study drug known as LY3041658 in participants with certain types of skin diseases. The study will measure how the body absorbs, breaks down and gets rid of LY3041658. It will last about 127 days for each participant, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.
Interventions
- DRUG Placebo
- DRUG LY3041658
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-11-08 |
| Est. Completion | 2019-03-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02896868
The ClinicalTrials.gov registry entry for NCT02896868 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02896868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02896868 about?
NCT02896868 is a clinical study titled "A Study of LY3041658 in Participants With Skin Diseases". The main purpose of this study is to investigate the safety and tolerability of the study drug known as LY3041658 in participants with certain types of skin diseases. The study will measure how the body absorbs, breaks down and gets rid of LY3041658. It will last about 127 days for each participant,...
What is the current status of trial NCT02896868?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-11-08. Estimated completion is 2019-03-19.
What interventions are being tested in trial NCT02896868?
The interventions under investigation include: Placebo (DRUG), LY3041658 (DRUG).
Who is sponsoring clinical trial NCT02896868?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.